Evaluating Simvastatin's Potential Role in Therapy
Status:
Completed
Trial end date:
2009-06-01
Target enrollment:
Participant gender:
Summary
The purpose of this study is to see how simvastatin, a cholesterol-lowering drug, affects
processes related to the development of Alzheimer's disease, including: 1) levels of a
substance called beta-amyloid-42 found in the spinal fluid surrounding the brain, 2) blood
flow in the brain, 3) inflammation in the brain, and 4) cognitive function.
Phase:
Phase 2
Details
Lead Sponsor:
University of Wisconsin, Madison
Collaborators:
American Federation for Aging Research Merck Sharp & Dohme Corp. National Institute on Aging (NIA) Paul Beeson Faculty Scholars Program Starr Foundation The Atlantic Philanthropies The John A. Hartford Foundation